Delving into the Latest Updates on Valomaciclovir Stearate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Valomaciclovir, Valomaciclovir stearate (USAN)

+ [6]

Target

DNA polymerase

Mechanism

DNA polymerase inhibitors(DNA polymerase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication-

Inactive Indication

Herpes ZosterInfectious MononucleosisMultiple Sclerosis

Originator Organization

Medivir AB

Active Organization-

Inactive Organization

Medivir AB

Epiphany Biosciences, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC33H58N6O5

InChIKeyACBSZTQIFTYFGH-IAPPQJPRSA-N

CAS Registry195156-77-5

This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.

Start Date01 Nov 2007

Sponsor / Collaborator

University of Minnesota

[+1]

100 Clinical Results associated with Valomaciclovir Stearate

Login to view more data

100 Translational Medicine associated with Valomaciclovir Stearate

Login to view more data

100 Patents (Medical) associated with Valomaciclovir Stearate

Login to view more data

13

Literatures (Medical) associated with Valomaciclovir Stearate

01 Dec 2017·Der HautarztQ4 · MEDICINE

Herpes simplex virus types I and II

Q4 · MEDICINE

Review

Author: El Hayderi, L ; Rübben, A ; Nikkels, A F

This review on herpes simplex virus type I and type II (HSV‑I, HSV‑II) summarizes recent developments in clinical manifestations and treatment interventions for primary and recurrent orolabial and genital herpes, as well as those regarding vaccination issues. Among the clinical presentations, the relationship between pyogenic granuloma and chronic HSV‑I infection; HSV-related folliculitis; verrucous HSV‑I and HSV‑II lesions; the role of recurrent HSV‑I infection in burning mouth syndrome; HSV‑I and HSV‑II infection of the periareolar area; zosteriform HSV; the "knife-cut sign"; and the preferential colonization and infection of preexisting dermatoses by HSV‑I or HSV‑II are discussed. The usual antiviral treatment regimens for primary and recurrent orolabial and genital herpes are compared to short-term and one-day treatment options. New anti-HSV‑I and anti-HSV‑II agents include amenavir, pritelivir, brincidofovir, valomaciclovir, and FV-100. Therapeutic or preventive vaccination against HSV‑I and HSV‑II infections still remains a highly desirable treatment aim, which, unfortunately, has no clinically relevant applications to date.

15 Jun 2017·Mini-Reviews in Medicinal ChemistryQ3 · MEDICINE

Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals

Q3 · MEDICINE

Review

Author: Krečmerová, Marcela

OBJECTIVEThe review covers basic principles of the prodrug strategy applied to antiviral nucleoside drugs or drug candidates. Specific role of amino acids as promoieties is explained with respect to transport mechanisms, pharmacokinetics and a low toxicity of compounds. Synthetic approaches to the most important representatives (compounds under clinical investigations or available on the market) are described, including valacyclovir, valganciclovir, valomaciclovir stearate, valcyclopropavir, valtorcitabine, valopicitabine and several attempts to amino acid modifications of antiretroviral nucleosides.METHODA special attention is paid to acyclic nucleoside phosphonates, where the phosphonic acid residue is esterified with a side-chain hydroxyl group of appropriate amino acid (serine, tyrosine) which can be used as single amino acid or as a part of dipeptides further modified on the terminal carboxyl function. The most advantageous pharmacokinetic profile and the best oral bioavailability were found in tyrosinebased prodrugs.RESULTS & CONCLUSIONStudies were performed successfully on 1-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (cidofovir), 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and some (R)-2- (phosphonomethoxy)propyl and 2-(phosphonomethoxy)ethyl derivatives including adefovir.

01 Mar 2017·Der HautarztQ4 · MEDICINE

Herpes-simplex-Virus Typ I und II

Q4 · MEDICINE

Review

Author: El Hayderi, L ; Rübben, A ; Nikkels, A F

This review on herpes simplex virus type I and type II (HSV-I, HSV-II) summarizes recent developments in clinical manifestations and treatment interventions for primary and recurrent orolabial and genital herpes, as well as those regarding vaccination issues. Among the clinical presentations, the relationship between pyogenic granuloma and chronic HSV-I infection; HSV-related folliculitis; verrucous HSV-I and HSV-II lesions; the role of recurrent HSV-I infection in burning mouth syndrome; HSV-I and HSV-II infection of the periareolar area; zosteriform HSV; the "knife-cut sign"; and the preferential colonization and infection of preexisting dermatoses by HSV-I or HSV-II are discussed. The usual antiviral treatment regimens for primary and recurrent orolabial and genital herpes are compared to short-term and one-day treatment options. New anti-HSV-I and anti-HSV-II agents include amenavir, pritelivir, brincidofovir, valomaciclovir, and FV-100. Therapeutic or preventive vaccination against HSV-I and HSV-II infections still remains a highly desirable treatment aim, which, unfortunately, has no clinically relevant applications to date.

100 Deals associated with Valomaciclovir Stearate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06275	-	-	DB15651

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpes Zoster	Phase 2	-	Medivir AB	-
Herpes Zoster	Phase 2	-	Medivir AB	-
Infectious Mononucleosis	Phase 2	US	Epiphany Biosciences, Inc.	-
Multiple Sclerosis	Phase 2	US	Epiphany Biosciences, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00575185 (Mono6, CTgov)	Phase 1/2	Infectious Mononucleosis	23	Valomaciclovir (Valomaciclovir)	omnqpnihza(vvsyerumun) = txzdlfcfws wbyybrkzms (kmygyndxkw, rsuxswmubp - ewdzkkruvo) View more	-	17 Mar 2015
				placebo (Placebo)	omnqpnihza(vvsyerumun) = qjxhrdbkhj wbyybrkzms (kmygyndxkw, qgvohvwydd - ezwlsfnnel) View more